News for Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics (GALT) is making strides in enhancing its belapectin analyses, according to their CEO, Joel Lewis. Recent developments were shared at the

NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. ( GALT), the leading developer of therapeutics that target galectin proteins, toda

Galectin Therapeutics (GALT) unveiled significant findings from the NAVIGATE study at the EASL 2025 Congress held in Amsterdam. The study focused on assessing b

Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reducti

Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices with belapectin vs

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. ( GALT), the leading developer of therapeutics that target galectin proteins, tod

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

Galectin Therapeutics director Harold Shlevin purchases $7,539 in common stock

U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 600 points on Friday. The Dow traded up 1.55% to 43,000.53 whil...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 300 points on Friday. The Dow traded up 1.82% to 43,111.11 while ...

U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 100 points on Friday. Following the market opening Friday, the Dow trade...

The stem cell market is experiencing positive growth due to several factors, including the increasing prevalence of chronic diseases, the need for drug...